Abrogation of uridine phosphorylase (UPase) leads to abnormalities in pyrimidine metabolism and host protection against 5-fluorouracil (5-FU) toxicity. We elucidated the effects on the metabolism and antitumor efficacy of 5-FU and capecitabine (N4-pentyloxycarbonyl-50-deoxy-5-fluorocytidine) in our UPase knockout (UPase / ) model. Treatment with 5-FU (85 mg/kg) or capecitabine (1,000 mg/kg) fiv...

Purpose: To determine the effect of melatonin in combination with capecitabine on proliferation and induction apoptosis MCF-7 SK-BR-3 breast cancer cell lines.Methods: The MTT assay (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) was performed to investigate lines half-maximal concentration (IC50) index. Expression apoptotic markers, Bax, Bcl-2, caspase-3 were measured by polym...

Capecitabine, an oral 5-fluorouracil prodrug, is currently used in the treatment of metastatic colorectal carcinoma and breast cancer. Fingerprints, also referred to as dermatoglyphics and characterized by the pattern of ridges and furrows on the fingertips, are used for identification by government agencies and personal electronic devices. Two women with breast cancer who were treated with cap...

Abrogation of uridine phosphorylase (UPase) leads to abnormalities in pyrimidine metabolism and host protection against 5-fluorouracil (5-FU) toxicity. We elucidated the effects on the metabolism and antitumor efficacy of 5-FU and capecitabine (N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) in our UPase knockout (UPase(-/-)) model. Treatment with 5-FU (85 mg/kg) or capecitabine (1,000 mg/kg)...

PURPOSE Previous preclinical studies suggested that concurrent capecitabine and radiation could be an effective new treatment modality for glioblastoma (GBM). In the current study, we investigate toxicity and response to this regimen and explore associations between gene expression and patient outcome. EXPERIMENTAL DESIGN Eighteen newly diagnosed GBM patients received concurrent capecitabine ...

BACKGROUND Thymidine phosphorylase (TP) is the key enzyme for capecitabine activation in tumour cells. AIMS To examine whether TP expression in tumour cells and stroma is predictive of the tumour response to capecitabine plus docetaxel chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS Tumour samples were available from 30 of 39 patients enrolled in a previou...

Introduction: Fluorine (F) magnetic resonance spectroscopy (MRS) can monitor the concentration and metabolism of fluorinated cancer drugs like 5-fluorouracil (5-FU) and its oral prodrug capecitabine in vivo [1]. Previous F MRS animal studies of capecitabine and 5-FU metabolism used a variety of anesthetic agents including injectable fluorinated compounds like Hypnovel and Hypnorm [2]. Fluorinat...

Gemcitabine is the only chemotherapeutic agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer. 5-fluorouracil or its oral pro-drug, capecitabine is the second most commonly used agent in this malignancy. Capecitabine or 5-fluorouracil is the second most common agent used either in second-line or as a radiosensitizer. Thromboembolism requi...

Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer. In an analysis of pooled results of two phase III studies, capecitabine provided advantages over intravenous fluorouracil (5-FU) plus leucovorin in patients with metastatic colorectal cancer. In another analysis, metastatic colorectal cancer patients who rece...

INTRODUCTION Sorafenib, an oral multikinase inhibitor, is the only systemic agent proven to be effective in patients with hepatocellular carcinoma (HCC). There are no approved second line systemic therapies in patients who have had disease progression on or are not eligible to sorafenib. CASE PRESENTATION We describe two cases of unresectable HCC that were treated with low, "metronomic" doses...